Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou

First Page		Document Content
Date: 2017-12-21 11:46:23		Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou Add to Reading List Source URL: selectabio.com Download Document from Source Website File Size: 560,96 KB Share Document on Facebook